Business Wire

500 Global and Ashdod Port Company Unveil Batch 2 of the Ashdod Port Accelerator by 500

6.9.2023 12:00:00 EEST | Business Wire | Press release

Share

Ashdod Port Company, the national port of Israel, and 500 Global, one of the world’s most active multi-stage venture capital firms, today unveil the graduating Israeli startups in Batch 2 of the Ashdod Port Accelerator by 500. These startups attended a rigorous 15-week program – with additional support from a team of Deloitte Israel experts – which gave them the opportunity to work with mentors on topics ranging from growth experiments and customer discovery interviews to testing product-market fit and fundraising. The program also includes participation in an accelerated proof-of-concept process, with the potential for investment by Ashdod Port Company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230906566212/en/

Batch 2 follows a successful Batch 1 cohort that included startups deploying new technologies at the port and some receiving additional investments from the Ashdod Port Company. Batch 2 of the program will culminate with Demo Day on September 13, 2023, in Tel Aviv. It will be held in person for a curated audience of industry leaders, ecosystem players, and 500 Global network partners. Attendees will hear presentations from a diverse group of startups that are providing solutions to needs in seaport operations, and are building the next generation of companies in sectors such as Industry 4.0, Logistics, Cyber, and Security.

"The investment and support for startups are part of our long-term strategy and future growth engine, which will provide a competitive advantage to ports adapted to the future, both in Israel and around the world,” said Shaul Schneider, Chairman of the Board of Directors of Ashdod Port. “This is one of the few accelerator programs operating in ports in the world. I’m proud of the collaboration with 500 Global, which has proven itself in recent years."

"We are delighted to host our Demo Day here in Israel on September 13 and thank the 500 Global team and the port workers who accompany them,” said Eli Bar Yosef, Acting CEO of Ashdod Port. “By supporting innovation, we are turning Ashdod Port into a smart port, with the aim of spreading the word overseas as well."

“This program is a truly unique initiative, thanks to our partner’s vision and belief that technology can play a central role in modernizing the maritime industry,” said Ee Ling Lim, Executive Director of Market Launch at 500 Global. “Ashdod may be a model for other ports and we believe that it is gaining momentum as a hub for Maritime and Logistics startup founders with exciting potential. Our second batch of startups has gained a solid foundation of corporate partnerships by working with Ashdod Port, and we believe they’re set up to grow in Israel and beyond.”

"500 Global's fruitful partnership with Ashdod Port is a game-changer, positioning the port as a true leader in maritime technology locally and globally," states Tal Chen, Partner at Deloitte Advisory. "This collaborative accelerator is the real deal – it's driving the growth of the Israeli tech scene and helping Ashdod Port shine in maritime technology. After seeing the success of Batch 1 startups, we're excited about Batch 2 Demo Day and confident it'll dish out great results for the Israeli maritime industry."

Tal Chen and Deloitte bring their unique knowledge, skills and experience to the POC processes at Port Ashdod, including the accelerator. This contributes great value to the different processes from spotting promising startups to guiding them through the POC process.

This exclusive event will also feature a panel of industry experts who will share insights on the role of startups in shaping supply chain innovation, as well as trends in the maritime and logistics sector in Israel and around the world. The panel will include representatives from major logistics companies, a startup founder, 500 Global and Ashdod Port Company.

Batch 2 startups are:

  • BenderTech is providing a Biometric electronic certificate ID Mobile Application, without Biometric Database, for fast entrance to multi-participant complexes, allows secure and efficient entrance.
  • Briefery captures workflow events to ensure process fidelity, tracking, tracing, and analyzing your data for increased efficiency.
  • Cynergy is providing a complete framework for an automated remediation ecosystem with the marketplace, SDK, and execution environment.
  • Flyz Robotics is a novel autonomous Platform for Deploying Sensors, Devices and Packages on Vertical Walls and other Hard to Reach Spaces.
  • Kiami is a knowledge-based technical support SaaS platform for industrial companies, enabling fast troubleshooting of machinery and product failures, and effective cross-team and cross-site knowledge collaboration sites.
  • Liquid360 is a patented software that contextualizes real-time security videos and sensor data empowering security teams to act faster and more effectively.
  • Magellanic is a Zero-Trust SaaS cybersecurity platform for access control of non-human identities, creating a "Unified Zero Trust Surface" for Machines, Users, APIs and Third Parties.
  • Pickommerce is an autonomous pick & pack robotic station with innovative grasping technology, designed to revolutionize the e-commerce logistics landscape.
  • ProxyFence is a SaaS platform for continuous API behavioral analysis and documentation.
  • SeeAll is a SaaS solution that enables manufacturers to visually track their materials throughout the entire process to ensure process integrity.
  • Treedis is a no-code platform that transforms industrial teams into connected workers to increase their efficiency and reduce their downtimes.
  • VIDIA has developed a platform based on video analytics for quality control, safety and predictive maintenance applicable for manufacturing, energy and marine industries with working customers.

To register to attend Demo Day, please visit the event page: Supply Chain Innovation - Ashdod Port Accelerator by 500 Global Demo Day .

Ashdod Port

Ashdod Port, The Port of Israel, is the leading seaport of the State of Israel with a strategically advantageous location. Experiencing growing demand, Ashdod Port has incorporated technological advancements into its operations and has inspired other ports around the world. Ashdod Port has collaborated with other institutions and ports to establish innovation embassies that promote growth within the industry. It frequently invests in new equipment and infrastructure for private and public benefit and supports promising early-stage entrepreneurs to bolster the maritime innovation ecosystem in Israel and globally.

500 Global

500 Global is a multi-stage venture capital firm with $2.4B in assets under management as of 30 June 2023 that invests in founders building fast-growing technology companies. We focus on markets where technology, innovation, and capital can unlock long-term value and drive economic growth. We work closely with key stakeholders and advise governments on how best to support entrepreneurial ecosystems so startups can thrive. 500 Global has backed over 5,000 founders representing more than 2,800 companies operating in 80+ countries. We have invested in 35+ companies valued at over $1 billion and 160+ companies valued at over $100 million (including private, public, and exited companies). Our 190+ team members are located in over 25 countries and bring experience as entrepreneurs, investors, and operators from some of the world’s leading technology companies.

DEMO DAY IS AN INVITATION-ONLY EVENT AND THE INTENDED AUDIENCE FOR THIS EVENT IS LIMITED TO "ACCREDITED INVESTORS" AS DEFINED IN REGULATION D UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MEMBERS OF THE PRESS. ALL CONTENT PROVIDED IN THE EVENT IS PROVIDED FOR GENERAL INFORMATIONAL OR EDUCATIONAL PURPOSES ONLY AND SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE BY 500 GLOBAL OR ANY OF ITS AFFILIATES OR AS AN OFFER TO SELL OR SOLICITATION OF INTEREST TO PURCHASE ANY SECURITIES. NO CONTENT OR INFORMATION CONTAINED IN THE EVENT IS OR IS INTENDED AS AN OFFER TO PROVIDE ANY INVESTMENT ADVISORY SERVICE OR FINANCIAL ADVICE BY 500 GLOBAL. UNDER NO CIRCUMSTANCES SHOULD ANY CONTENT HEREIN OR IN THE EVENT BE CONSTRUED AS FUND MARKETING MATERIALS BY PROSPECTIVE INVESTORS CONSIDERING AN INVESTMENT INTO ANY 500 GLOBAL INVESTMENT FUND. INCLUSION AS A PRESENTING COMPANY IN DEMO DAY DOES NOT NECESSARILY CONFIRM INVESTMENT BY A 500 GLOBAL FUND IN SUCH COMPANY. 500 GLOBAL HAS NOT TAKEN ANY ACTIONS TO QUALIFY THE DISTRIBUTION OF THE EVENT UNDER THE SECURITIES LAWS OF ANY JURISDICTION WHERE ACTION FOR THAT PURPOSE IS REQUIRED. PERSONS OUTSIDE OF THE UNITED STATES WHO VIEW THE EVENT MUST OBSERVE ANY APPLICABLE LAWS AND RESTRICTIONS RELATING TO VIEWING THIS EVENT AND ANY RELATED ACTIVITIES OUTSIDE OF THE UNITED STATES.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

JT Eger
Communications at 500 Global
press@500.co

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release

A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release

Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release

Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release

Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye